Deborah Morosini

4.5k total citations · 1 hit paper
33 papers, 1.9k citations indexed

About

Deborah Morosini is a scholar working on Pulmonary and Respiratory Medicine, Cancer Research and Oncology. According to data from OpenAlex, Deborah Morosini has authored 33 papers receiving a total of 1.9k indexed citations (citations by other indexed papers that have themselves been cited), including 18 papers in Pulmonary and Respiratory Medicine, 14 papers in Cancer Research and 12 papers in Oncology. Recurrent topics in Deborah Morosini's work include Lung Cancer Treatments and Mutations (11 papers), Cancer Genomics and Diagnostics (10 papers) and Advanced Breast Cancer Therapies (3 papers). Deborah Morosini is often cited by papers focused on Lung Cancer Treatments and Mutations (11 papers), Cancer Genomics and Diagnostics (10 papers) and Advanced Breast Cancer Therapies (3 papers). Deborah Morosini collaborates with scholars based in United States and Israel. Deborah Morosini's co-authors include Philip J. Stephens, Jeffrey S. Ross, Siraj M. Ali, Vincent A. Miller, Doron Lipson, Gary A. Palmer, Roman Yelensky, Kai Wang, Juliann Chmielecki and Geoff Otto and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and Clinical Cancer Research.

In The Last Decade

Deborah Morosini

30 papers receiving 1.9k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

An Oncogenic NTRK Fusion in a Patient with Soft-Tissue Sarcoma with Response to the Tropomyosin-Related Kinase Inhibitor LOXO-101

2015 302 citations Robert C. Doebele, Lara E. Davis et al. Cancer Discovery profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Deborah Morosini United States	18	1.1k	767	545	449	438	33	1.9k
So Young Kang South Korea	29	895 0.8×	714 0.9×	634 1.2×	532 1.2×	366 0.8×	92	2.1k
James Suh United States	21	1.0k 0.9×	519 0.7×	820 1.5×	577 1.3×	331 0.8×	72	1.9k
Lorenza Pecciarini Italy	17	860 0.8×	836 1.1×	356 0.7×	349 0.8×	193 0.4×	42	2.1k
Jau‐Yu Liau Taiwan	25	841 0.8×	488 0.6×	414 0.8×	256 0.6×	422 1.0×	79	1.7k
Seiji Sakata Japan	18	1.1k 1.0×	766 1.0×	1.2k 2.3×	561 1.2×	201 0.5×	39	2.2k
Susanna Cappia Italy	24	766 0.7×	651 0.8×	748 1.4×	363 0.8×	387 0.9×	56	2.0k
Isabelle Soubeyran France	27	844 0.8×	346 0.5×	541 1.0×	368 0.8×	247 0.6×	70	1.8k
Erminia Manfrin Italy	30	1.4k 1.3×	578 0.8×	698 1.3×	466 1.0×	497 1.1×	99	2.4k
Leonardo Faoro United States	16	691 0.6×	686 0.9×	344 0.6×	192 0.4×	248 0.6×	36	1.6k
Ettore Macrì Italy	14	1.1k 1.0×	449 0.6×	306 0.6×	291 0.6×	400 0.9×	20	1.8k

Countries citing papers authored by Deborah Morosini

Since Specialization

Citations

This map shows the geographic impact of Deborah Morosini's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Deborah Morosini with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Deborah Morosini more than expected).

Fields of papers citing papers by Deborah Morosini

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Deborah Morosini. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Deborah Morosini. The network helps show where Deborah Morosini may publish in the future.

Co-authorship network of co-authors of Deborah Morosini

This figure shows the co-authorship network connecting the top 25 collaborators of Deborah Morosini. A scholar is included among the top collaborators of Deborah Morosini based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Deborah Morosini. Deborah Morosini is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Sireci, Anthony, Deborah Morosini, & S. Michael Rothenberg. (2019). P1.01-101 Efficacy of Immune Checkpoint Inhibition in RET Fusion Positive Non-Small Cell Lung Cancer Patients. Journal of Thoracic Oncology. 14(10). S401–S401. 2 indexed citations

Ebata, Kevin, Flemming Hansen, Deborah Morosini, et al.. (2018). TRK wild-type and fusion protein expression in solid tumors: Characterization by immunohistochemistry and in situ hybridization. Annals of Oncology. 29. vi27–vi27. 3 indexed citations

Parachoniak, Christine A., Andrew Rankin, Ryan J. Hartmaier, et al.. (2017). Exceptional durable response to everolimus in a patient with biphenotypic breast cancer harboring anSTK11variant. Molecular Case Studies. 3(5). a000778–a000778. 19 indexed citations

Balch, Alan, Charles M. Balch, Al B. Benson, et al.. (2016). Recommendations for the Role of Clinical Pathways in an Era of Personalized Medicine. The American Journal of Managed Care. 22. 1 indexed citations

Burgoyne, Adam M., Fei Gao, Juliann Chmielecki, et al.. (2016). Hedgehog pathway dysregulation contributes to the pathogenesis of human gastrointestinal stromal tumors via GLI-mediated activation of KIT expression. Oncotarget. 7(48). 78226–78241. 23 indexed citations

Klempner, Samuel J., Thomas K. Lee, Mark G. Erlander, et al.. (2016). BRAF V600E Mutations in High-Grade Colorectal Neuroendocrine Tumors May Predict Responsiveness to BRAF–MEK Combination Therapy. Cancer Discovery. 6(6). 594–600. 74 indexed citations

Doebele, Robert C., Lara E. Davis, Aria Vaishnavi, et al.. (2015). An Oncogenic NTRK Fusion in a Patient with Soft-Tissue Sarcoma with Response to the Tropomyosin-Related Kinase Inhibitor LOXO-101. Cancer Discovery. 5(10). 1049–1057. 302 indexed citations breakdown →

McMahon, Caitlin, Casey Williams, Brian Leyland‐Jones, et al.. (2015). A metastatic colon adenocarcinoma harboring BRAF V600E has a durable major response to dabrafenib/trametinib and chemotherapy. OncoTargets and Therapy. 8. 3561–3561. 7 indexed citations

Ross, Jeffrey S., Siraj M. Ali, Kai Wang, et al.. (2015). Comprehensive genomic profiling of inflammatory breast cancer cases reveals a high frequency of clinically relevant genomic alterations. Breast Cancer Research and Treatment. 154(1). 155–162. 61 indexed citations

10.

Ross, Jeffrey S., Sunil Badve, Kai Wang, et al.. (2015). Genomic Profiling of Advanced-Stage, Metaplastic Breast Carcinoma by Next-Generation Sequencing Reveals Frequent, Targetable Genomic Abnormalities and Potential New Treatment Options. Archives of Pathology & Laboratory Medicine. 139(5). 642–649. 55 indexed citations

11.

Chmielecki, Juliann, Jeffrey S. Ross, Kai Wang, et al.. (2014). Oncogenic Alterations in ERBB2/HER2 Represent Potential Therapeutic Targets Across Tumors From Diverse Anatomic Sites of Origin. The Oncologist. 20(1). 7–12. 75 indexed citations

12.

Palma, Norma Alonzo, Siraj M. Ali, Kai Wang, et al.. (2014). Durable Response to Crizotinib in a MET-Amplified, KRAS-Mutated Carcinoma of Unknown Primary. Case Reports in Oncology. 7(2). 503–508. 23 indexed citations

13.

Sharman, Jeff P., Juliann Chmielecki, Deborah Morosini, et al.. (2014). Vemurafenib Response in 2 Patients With Posttransplant Refractory BRAF V600E–Mutated Multiple Myeloma. Clinical Lymphoma Myeloma & Leukemia. 14(5). e161–e163. 41 indexed citations

14.

Ross, Jeffrey S., Kai Wang, Geoff Otto, et al.. (2014). Targeted next-generation sequencing (NGS) of carcinoma of unknown primary site (CUP): Actionable genomic alterations (GA) and new routes to targeted therapies.. Journal of Clinical Oncology. 32(15_suppl). 11048–11048. 1 indexed citations

15.

Ali, Siraj M., Sai‐Hong Ignatius Ou, Jie He, et al.. (2014). Identifying ALK rearrangements that are not detected by FISH with targeted next-generation sequencing of lung carcinoma.. Journal of Clinical Oncology. 32(15_suppl). 8049–8049. 11 indexed citations

16.

Ross, Jeffrey S., Christine E. Sheehan, Geoff Otto, et al.. (2014). Next-generation sequencing reveals frequent consistent genomic alterations in small cell undifferentiated lung cancer. Journal of Clinical Pathology. 67(9). 772–776. 78 indexed citations

17.

Ross, Jeffrey S., Janne V. Rand, Laurie M. Gay, et al.. (2014). Next-generation sequencing of adrenocortical carcinoma reveals new routes to targeted therapies. Journal of Clinical Pathology. 67(11). 968–973. 51 indexed citations

18.

Parsels, Leslie A., Yushen Qian, Daria M. Tanska, et al.. (2011). Assessment of Chk1 Phosphorylation as a Pharmacodynamic Biomarker of Chk1 Inhibition. Clinical Cancer Research. 17(11). 3706–3715. 67 indexed citations

19.

Hong, Xin, Andreas Herrmann, Karen L. Reckamp, et al.. (2011). Antiangiogenic and Antimetastatic Activity of JAK Inhibitor AZD1480. Cancer Research. 71(21). 6601–6610. 93 indexed citations

20.

Morgan, Meredith A., Leslie A. Parsels, Lili Zhao, et al.. (2010). Mechanism of Radiosensitization by the Chk1/2 Inhibitor AZD7762 Involves Abrogation of the G2 Checkpoint and Inhibition of Homologous Recombinational DNA Repair. Cancer Research. 70(12). 4972–4981. 249 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact